Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash from Operations (2022 - 2025)

Stoke Therapeutics has reported Cash from Operations over the past 4 years, most recently at 30454000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 30454000.0 for Q4 2025, down 31.31% from a year ago — trailing twelve months through Dec 2025 was 45585000.0 (up 152.49% YoY), and the annual figure for FY2025 was 45585000.0, up 152.49%.
  • Cash from Operations for Q4 2025 was 30454000.0 at Stoke Therapeutics, roughly flat from 30366000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for STOK hit a ceiling of 131827000.0 in Q1 2025 and a floor of 30454000.0 in Q4 2025.
  • Median Cash from Operations over the past 4 years was 21707500.0 (2023), compared with a mean of 9637437.5.
  • Biggest five-year swings in Cash from Operations: tumbled 165.73% in 2023 and later skyrocketed 636.62% in 2025.
  • Stoke Therapeutics' Cash from Operations stood at 22373000.0 in 2022, then rose by 7.71% to 20649000.0 in 2023, then dropped by 12.32% to 23193000.0 in 2024, then plummeted by 31.31% to 30454000.0 in 2025.
  • The last three reported values for Cash from Operations were 30454000.0 (Q4 2025), 30366000.0 (Q3 2025), and 25422000.0 (Q2 2025) per Business Quant data.